Navigation Links
Common Flu Strain Resistant to Popular Antiviral Drug
Date:1/8/2009

But other medications are available that work, CDC officials stress

THURSDAY, Jan. 8 (HealthDay News) -- The most common strain of flu this season is resistant to the popular antiviral drug Tamiflu, but government health officials said Thursday there is no reason to panic.

The fact that the flu season so far has been slow, and that other drugs work well against this particular flu virus, has health officials adopting a watchful attitude for now.

While the cause of the mutation that made the virus resistant to Tamiflu (oseltamivir) isn't known, experts suspect it was caused by the wide use of Tamiflu in other countries to treat upper respiratory infections.

There were reports last year from Europe and other countries that a certain type of flu -- H1N1 -- was resistant to oseltamivir, according to Dr. Joseph Bresee, chief of flu prevention at the U.S. Centers for Disease Control and Prevention.

This year, the CDC was on the lookout for flu resistance to Tamiflu in the United States and, sure enough, it showed up. Moreover, the proportion of the strain that is resistant has gone up from around 10 percent last year to all of the H1N1 strains this year, Bresee said.

Two weeks ago, the CDC issued new guidelines urging doctors to test suspected flu cases to see if they are influenza A or influenza B, and if they are A, whether they are H1 or H3 viruses, Bresee said.

"We didn't want to make a big deal out of this," Bresee said. "We think it's interesting. We think it's worth monitoring closely, but we are still watching. When we see more, then we will get a better sense of what the public health impact of it is. We don't have a good feel of that yet."

The resistant strain is the most common type of flu circulating in the United States right now, but the season is early and the number of cases is low, Bresee said.

As more flu cases are reported, other strains of the virus may become more common, Bresee added.

"What happens frequently is that one type of flu will circulate at one time in the season and be replaced by another type later in the season, so in a week's time, a month's time, we may have mostly H3s or mostly Bs, which oseltamivir works wonderfully for," he explained.

To be most effective, Tamiflu, made by Roche, needs to taken within 48 hours after flu symptoms appear, Bresee said. "Generally, antivirals for influenza are underused in the U.S.," he added.

Most people with flu are not treated, Bresee noted. "Clearly, it's a self-limited disease and you will get over it," he said.

Bresee noted there are alternatives to Tamiflu, including Relenza (zanamivir) made by GlaxoSmithKline. "The viruses that we are seeing that are resistant to Tamiflu are sensitive to zanamivir," he said.

Zanamivir has some limitations, Bresee said. It can't be given to young children and patients with certain lung diseases.

Other treatment options include the antiviral rimantadine (brand name Flumadine).

Bresee added that all the circulating flu stains are prevented by the flu vaccine, and it's not too late to get vaccinated. "Folks who haven't gotten the vaccine so far can still go get it," he said.

Dr. Pascal James Imperato, dean and Distinguished Service Professor of the Graduate Program in Public Health at SUNY Downstate Medical Center in New York City, thinks resistance to Tamiflu developed because of its use in other countries to treat upper respiratory infections.

"The emerging resistance of H1N1 influenza strains to oseltamivir was first noted a few years ago," Imperato said. "At present, based on analyses of H1N1 isolates from 16 countries in 2008, some 31 percent demonstrated resistance to Tamiflu."

Tamiflu resistance has not been documented for the two other common current human influenza strains, H3N2 and influenza B, or for avian influenza (H5N1), Imperato said.

"On the face of it, the emergence of resistance in the presence of limited drug use would seem unusual," Imperato said. "However, in many areas of the world, there is significant Tamiflu use for upper respiratory infections. It is believed that minor mutations in the H1N1 virus can in effect block the action of Tamiflu," he said.

It is important to note that no H1N1 influenza resistance to Relenza has developed, Imperato said. "This is the other drug in the neuraminidase group used to prevent and treat influenza," he said.

Flu usually causes about 36,000 deaths in the United States each year. Most deaths are among the elderly, very young or those with medical conditions such as asthma or heart disease. Pneumonia resulting from flu is usually the fatal complication.

More information

For more on the flu, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Joseph Bresee, M.D., chief, Epidemiology and Prevention Branch Influenza Division, U.S. Centers for Disease Control and Prevention, Atlanta; Pascal James Imperato, M.D., M.P.H., Dean and Distinguished Service Professor, Graduate Program in Public Health, SUNY Downstate Medical Center, New York City


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Flu Strain Resistant to Popular Antiviral Drug
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is ... back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh is ... partner with Cupron® to provide customers with a game changing chair that is ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... San Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... San Francisco, is proud to announce a new, informational blog post on insurance options. ... tooth surgery, checking insurance plans may help save time and money. Visiting an in-network ...
(Date:5/26/2017)... ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of ... Cross” is the creation of published authors, Bob and Margaret Massey. Bob Massey is ... is "panther quick and leather tough." His love for others is apparent in all ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
Breaking Medicine Technology: